Residency · Residency · Allergy Immunology

B Cell Biology and Immunoglobulin Structure

B Cell Development

Bone Marrow Stages

B cell development begins in the bone marrow, where hematopoietic stem cells give rise to common lymphoid progenitors (CLPs) under the influence of IL-7, a critical cytokine for lymphoid lineage commitment and survival. The earliest committed B cell precursor, the pro-B cell, initiates immunoglobulin heavy chain gene rearrangement, beginning with D-to-J joining followed by V-to-DJ joining. This process requires the recombination-activating gene products RAG1 and RAG2 for the DNA cleavage and recombination steps, and terminal deoxynucleotidyl transferase (TdT) for the addition of non-templated N-nucleotides at the junctional regions, which contributes substantially to antibody diversity. The transcription factors E2A, EBF (early B cell factor), and Pax5 are essential for B lineage commitment, with Pax5 playing a particularly critical role in maintaining B cell identity by activating B cell-specific genes and repressing genes associated with alternative lineages.

Upon successful productive rearrangement of the heavy chain, the pro-B cell transitions to the pre-B cell stage. Here, the mu heavy chain pairs with a surrogate light chain composed of VpreB and lambda5 (also designated Igll1) to form the pre-B cell receptor (pre-BCR). Signaling through the pre-BCR is a critical developmental checkpoint that verifies the functionality of the rearranged heavy chain. Successful pre-BCR signaling triggers several essential processes: proliferative expansion of the pre-B cell clone, allelic exclusion of the second heavy chain allele (ensuring monospecificity), and initiation of light chain gene rearrangement.

Light chain rearrangement follows an ordered hierarchy. The kappa locus is rearranged first; only if kappa rearrangement is non-productive on both alleles does rearrangement of the lambda locus proceed. This hierarchical process accounts for the approximately 2:1 kappa-to-lambda ratio observed in the normal human B cell repertoire. Once a functional light chain is produced, it pairs with the heavy chain to form a complete IgM molecule that is expressed on the cell surface, marking the transition to the immature B cell stage.

Central tolerance checkpoints operate at the immature B cell stage to eliminate or edit self-reactive B cells. Receptor editing, the primary mechanism, involves secondary light chain gene rearrangement that replaces the self-reactive specificity with a new, potentially non-self-reactive one. If receptor editing fails to eliminate self-reactivity, clonal deletion through apoptosis occurs. The stringency of these tolerance mechanisms is remarkable: approximately 75 percent of initial B cell specificities generated by random V(D)J recombination are self-reactive and are eliminated during development.

Peripheral B Cell Maturation

Immature B cells that survive central tolerance checkpoints emigrate from the bone marrow as transitional B cells (designated T1 and T2), which undergo further selection in the spleen. Transitional B cells are exquisitely sensitive to BCR crosslinking and undergo apoptosis rather than activation upon encounter with self-antigen, providing an additional peripheral tolerance checkpoint. Those that survive mature into naive B cells co-expressing IgM and IgD on their surface and populate the follicles of secondary lymphoid organs.

B cell survival in the periphery is critically dependent on TNF family cytokines, particularly BAFF (B cell activating factor, also known as BLyS) and APRIL (a proliferation-inducing ligand). These cytokines signal through three receptors with differential expression on B cell subsets: BAFF-R (the primary BAFF receptor on mature naive B cells), TACI (expressed on marginal zone B cells and plasma cells), and BCMA (expressed on long-lived plasma cells in the bone marrow). Deficiency of TACI is associated with common variable immunodeficiency (CVID) and selective IgA deficiency, underscoring the importance of these survival signals for humoral immunity. The therapeutic monoclonal antibody belimumab, which neutralizes BAFF, is approved for the treatment of systemic lupus erythematosus, where excessive BAFF-mediated B cell survival contributes to autoantibody production.

<image>A vertical flowchart depicting B cell development from bone marrow to periphery. Starting with hematopoietic stem cell at top, progressing through: CLP, pro-B cell (showing heavy chain D-J then V-DJ rearrangement), pre-B cell (showing pre-BCR with surrogate light chain), immature B cell (surface IgM), transitional B cell, and mature naive B cell (IgM+IgD+). At each stage, show key surface markers (CD19, CD20, CD34, etc.), active transcription factors, and critical checkpoints. Include receptor editing and clonal deletion at the immature B cell stage. Branching arrows in periphery showing follicular B cell, marginal zone B cell, and B-1 B cell fates. Color gradient from red (bone marrow) to blue (periphery).</image>

Immunoglobulin Structure

Basic Antibody Architecture

Immunoglobulins are Y-shaped glycoprotein molecules composed of two identical heavy chains and two identical light chains, held together by inter-chain disulfide bonds. Each heavy chain consists of a variable domain (VH) followed by constant domains: CH1, a flexible hinge region, CH2, and CH3 in the case of IgG. IgM and IgE diverge from this pattern by possessing an additional CH4 domain in place of the hinge region. Each light chain consists of a variable domain (VL) and a single constant domain (CL), which may be of either kappa or lambda type. Intra-domain disulfide bonds stabilize the characteristic immunoglobulin fold of each domain.

The antibody molecule can be functionally divided into two regions. The Fab fragment (fragment antigen binding), encompassing VH-CH1 and VL-CL, contains the antigen-binding site and determines the specificity of the antibody. The Fc fragment (fragment crystallizable), consisting of CH2 and CH3, mediates effector functions including complement activation, Fc receptor binding on phagocytes and other immune cells, and transcytosis across epithelial barriers.

Antigen-Binding Site

The antigen-binding site is formed by six hypervariable loops, three from the heavy chain variable domain and three from the light chain variable domain, termed complementarity-determining regions (CDR1, CDR2, and CDR3). The CDR3 of the heavy chain is the most diverse region, spanning the V-D-J junction where the combinatorial and junctional diversity mechanisms generate the greatest sequence variation, and it is the primary determinant of antigen specificity. The four framework regions (FR1-FR4) within each variable domain provide the structural scaffold that positions the CDRs for antigen engagement. The unique antigenic determinant created by the specific combination of CDR sequences is termed the idiotype.

Immunoglobulin Classes and Subclasses

The five immunoglobulin classes differ in their heavy chain constant regions and serve distinct functional roles in humoral immunity. IgG constitutes approximately 75 percent of serum immunoglobulin at a concentration of approximately 10 mg/mL and is subdivided into four subclasses. | IgG Subclass | % of Total IgG | Half-Life | Complement Activation | Key Properties |

IgG1 (65 percent of total IgG) mediates anti-protein responses and efficiently fixes complement, with a half-life of 21 days. IgG2 (25 percent) is particularly important for anti-polysaccharide responses and is a relatively poor complement activator. IgG3 (7 percent) is the most potent complement activator among the IgG subclasses but has the shortest half-life (7 days) due to its elongated hinge region, which increases susceptibility to proteolysis and reduces FcRn binding efficiency. IgG4 (3 percent) has several unique properties: it undergoes Fab-arm exchange in vivo, generating bispecific antibodies with two different antigen-binding arms; it does not fix complement; and it increases with prolonged or high-dose antigen exposure, serving as a blocking antibody that competes with IgE for allergen binding. This latter property is central to the mechanism of allergen immunotherapy.

IgA represents approximately 15 percent of serum immunoglobulin and exists in two subclasses. IgA1 predominates in serum and possesses an extended hinge region that is susceptible to cleavage by bacterial IgA1 proteases produced by respiratory pathogens. IgA2 predominates in gut secretions and is resistant to these proteases. Secretory IgA, the predominant antibody at mucosal surfaces, is a dimeric molecule in which two IgA monomers are joined by the J chain and wrapped in the secretory component (derived from the polymeric immunoglobulin receptor, pIgR, during transcytosis across epithelial cells).

IgM constitutes approximately 10 percent of serum immunoglobulin and circulates primarily as a pentamer joined by the J chain, although it exists as a monomer on the surface of naive B cells. IgM is the most efficient complement activator: a single IgM pentamer provides sufficient C1q binding sites for classical pathway activation, compared to the requirement for two IgG molecules in close proximity. IgM is the first antibody produced in a primary immune response and provides crucial early defense before class-switched antibodies are generated.

IgE is present at vanishingly low serum concentrations (0.0003 mg/mL, constituting only 0.003 percent of total immunoglobulin). Despite its low concentration, IgE has enormous biologic potency because it binds the high-affinity FcepsilonRI receptor with extraordinary avidity (Kd approximately 10^-10 M). While the serum half-life of free IgE is only about 2 days, IgE bound to mast cell FcepsilonRI persists for weeks to months. IgE possesses no hinge region but has an extra CH4 domain. Its primary physiologic role is defense against parasites, but it also mediates type I hypersensitivity reactions. IgE does not cross the placenta and does not activate complement.

IgD represents less than 1 percent of serum immunoglobulin and is co-expressed with IgM on the surface of naive B cells through alternative mRNA splicing. The function of secreted IgD remains incompletely understood, though evidence suggests a role in upper respiratory mucosal immunity and basophil activation.

<image>A detailed structural diagram of immunoglobulin G showing the Y-shaped molecule with labeled components: two heavy chains (blue) and two light chains (green). Labeled regions include: VH, VL, CH1, CH2, CH3, CL, hinge region, Fab and Fc fragments, CDR loops at the antigen-binding sites, inter-chain disulfide bonds, and the N-linked glycosylation site at Asn297 in CH2. Adjacent panels compare the structural differences among IgG, IgA (dimeric with J chain and secretory component), IgM (pentameric with J chain), and IgE (extra CH4 domain, no hinge). Include a small table showing serum concentration, half-life, and complement-fixing ability for each isotype.</image>

Class Switch Recombination (CSR) and Somatic Hypermutation (SHM)

Class Switch Recombination

Class switch recombination is the process by which an activated B cell changes the constant region of its heavy chain from IgM to IgG, IgA, or IgE, thereby altering the effector function of the antibody while retaining the same antigen specificity. CSR occurs primarily within the germinal center but can also take place at extrafollicular sites. The process involves DNA recombination between repetitive switch regions located upstream of each constant region gene, with deletion of the intervening DNA. The essential enzyme for CSR is activation-induced cytidine deaminase (AID), which initiates the process by deaminating cytosine residues to uracil within the switch regions, creating mismatches that are processed by base excision repair and mismatch repair pathways into the double-strand breaks necessary for recombination.

The direction of class switching is governed by the cytokine environment. IL-4 and IL-13 direct switching to IgE and IgG4. IFN-gamma promotes switching to IgG1 and IgG3 in humans. TGF-beta drives switching to IgA. IL-21 promotes IgG1 and IgG3 while inhibiting IgE switching, an important regulatory function that limits potentially harmful IgE production.

Deficiency of AID causes hyper-IgM syndrome type 2, an autosomal recessive condition characterized by elevated IgM with absent IgG, IgA, and IgE, because B cells are unable to perform class switch recombination. Similarly, deficiency of UNG (uracil-N-glycosylase), which processes the AID-generated uracil residues, causes hyper-IgM syndrome type 5 with a comparable phenotype.

Somatic Hypermutation

Somatic hypermutation is a process by which point mutations are introduced into the variable region genes of immunoglobulin at a rate approximately one million-fold higher than the basal mutation rate (approximately 10^-3 per base pair per cell division). This process occurs in the dark zone of the germinal center, where activated B cells (centroblasts) undergo rapid proliferation. AID is also the essential initiating enzyme for SHM, targeting the variable region DNA for deamination.

The mutations introduced by SHM generate a population of B cell clones with variant antibodies, some with higher and some with lower affinity for the antigen. These variants are then subjected to stringent selection in the germinal center light zone, where centrocytes compete for limited antigen displayed on follicular dendritic cells (FDCs) and for T cell help from Tfh cells. Clones with higher-affinity BCRs are more effective at capturing and presenting antigen and thus receive preferential survival signals through CD40L-CD40 interactions and IL-21 from Tfh cells. Lower-affinity clones fail to compete effectively and undergo apoptosis; the resulting cellular debris is cleared by tingible body macrophages, a histologic hallmark of the germinal center. This iterative process of mutation and selection, termed affinity maturation, progressively enhances the quality of the antibody response over time. Importantly, somatic hypermutation does not occur in T cells; the TCR does not undergo SHM.

Germinal Center Reaction

The germinal center reaction is initiated when activated B cells enter a lymphoid follicle and receive cognate help from Tfh cells. The germinal center is organized into two functional zones. The dark zone houses centroblasts undergoing rapid cell division and somatic hypermutation. Centroblasts then migrate to the light zone as centrocytes, where they test their mutated BCR against antigen presented on the dendritic processes of follicular dendritic cells. Centrocytes with improved antigen affinity receive survival signals from Tfh cells (via CD40L and IL-21), while those with unchanged or decreased affinity undergo apoptosis.

The output of the germinal center reaction includes two critical cell types: long-lived plasma cells, which migrate to the bone marrow and produce high-affinity, class-switched antibodies for months to years, and memory B cells, which circulate and provide rapid recall responses upon re-encounter with the antigen.

Germinal center function is impaired in several immunodeficiency syndromes. X-linked hyper-IgM syndrome, caused by CD40L deficiency, prevents the T-B cell interaction necessary for germinal center formation and class switching. ICOS deficiency similarly impairs germinal center reactions by disrupting Tfh cell function. SAP deficiency, which causes X-linked lymphoproliferative disease (XLP), prevents the stable T-B cell interactions required for germinal center formation.

B Cell Subsets and Functions

Follicular B Cells (B-2)

Follicular B cells constitute the majority of mature B cells in the spleen and lymph nodes. They are the principal participants in T-dependent immune responses and the germinal center reaction, generating high-affinity, class-switched antibodies and long-lived memory. Follicular B cells recirculate between secondary lymphoid organs and are the primary mediators of vaccine-induced humoral immunity.

Marginal Zone B Cells

Marginal zone B cells occupy a unique anatomic niche in the splenic marginal zone, where they serve as first responders to blood-borne antigens. They are specialized for rapid T-independent responses and can rapidly produce IgM and, to some extent, IgG antibodies without requiring germinal center maturation. They express high levels of complement receptors (CR1 and CR2) and TLRs, enabling them to detect complement-opsonized pathogens and microbial products. The functional importance of marginal zone B cells is illustrated by the increased susceptibility to encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis) observed in asplenic patients, in whom this B cell compartment is absent.

B-1 B Cells

B-1 B cells are a self-renewing population predominantly found in the peritoneal and pleural cavities. They produce natural antibodies, polyreactive IgM molecules that recognize common microbial determinants and self-antigens, including anti-blood group antibodies (isohemagglutinins). B-1 B cells function largely independently of T cell help and may contribute to both early innate-like defense and, when dysregulated, to autoimmune disease.

Regulatory B Cells (Bregs)

Regulatory B cells are defined functionally by their production of the immunosuppressive cytokines IL-10 and IL-35 rather than by a unique surface marker phenotype. They play important roles in transplant tolerance, autoimmune disease regulation, and modulating inflammatory responses. Their identification relies primarily on demonstration of IL-10 production capacity, and multiple phenotypically distinct B cell subsets can function as Bregs.

FcR Biology and Effector Functions

Fc Receptor Classes

Fc receptors translate antibody-mediated recognition into cellular immune responses. The major classes are functionally distinguished by their affinity, cellular distribution, and signaling properties. FcgammaRI (CD64) is a high-affinity IgG receptor expressed on monocytes, macrophages, and dendritic cells that contains an activating ITAM signaling motif. FcgammaRIIA (CD32A) is a low-affinity activating receptor with broad cellular expression. FcgammaRIIB (CD32B) is the sole inhibitory FcgammaR, expressed on B cells and containing an ITIM signaling motif that provides negative feedback to suppress B cell activation. FcgammaRIIIA (CD16A) is a low-affinity activating receptor on NK cells and macrophages that mediates antibody-dependent cellular cytotoxicity (ADCC).

FcepsilonRI, the high-affinity IgE receptor (Kd approximately 10^-10 M), is expressed as a tetrameric complex (alpha-beta-gamma2) on mast cells and basophils, where crosslinking by multivalent antigen triggers degranulation. On dendritic cells, monocytes, and eosinophils, it exists as a trimeric form (alpha-gamma2) that facilitates IgE-mediated antigen capture and presentation rather than degranulation. FcalphaRI (CD89) is the IgA receptor on neutrophils and monocytes. FcRn (neonatal Fc receptor) is a recycling receptor that determines IgG half-life by rescuing endocytosed IgG from lysosomal degradation and mediates placental transfer of maternal IgG to the fetus. FcRn is the therapeutic target of efgartigimod (approved for myasthenia gravis) and rozanolixizumab, which accelerate IgG catabolism to reduce pathogenic autoantibody levels.

Effector Functions

The principal antibody-mediated effector functions include ADCC (mediated by FcgammaRIIIA on NK cells engaging IgG-coated target cells), opsonization and phagocytosis (mediated by FcgammaRI and FcgammaRIIA on macrophages and neutrophils), complement activation through the classical pathway (with an efficiency hierarchy of IgM > IgG3 > IgG1 >> IgG2, while IgG4 does not fix complement), and mast cell degranulation (triggered by crosslinking of IgE bound to FcepsilonRI).

<image>An illustration showing the key Fc receptors and their cellular distribution. Central panel shows an IgG molecule with its Fc region highlighted. Surrounding panels show different cell types with their Fc receptors: (1) NK cell with FcgammaRIIIA mediating ADCC against a target cell, (2) macrophage with FcgammaRI performing opsonophagocytosis, (3) B cell with inhibitory FcgammaRIIB providing negative feedback, (4) mast cell with FcepsilonRI binding IgE and showing crosslinking-induced degranulation, and (5) endothelial cell with FcRn recycling IgG to extend half-life. Each receptor labeled with CD number, signaling motif (ITAM vs ITIM), and affinity.</image>

Key Clinical Pearls

• Pre-BCR signaling defects (Btk in X-linked agammaglobulinemia) arrest B cell development at the pre-B stage, causing agammaglobulinemia with absent B cells
• IgG4 is unique: undergoes Fab-arm exchange, does not fix complement, and increases with prolonged antigen exposure (e.g., beekeepers, immunotherapy)
• AID deficiency causes autosomal recessive hyper-IgM syndrome; distinguish from X-linked hyper-IgM (CD40L deficiency) which also impairs germinal center formation
• IgG subclass deficiency (especially IgG2) predisposes to recurrent sinopulmonary infections with encapsulated organisms
• FcRn determines IgG half-life (~21 days for IgG1/2/4, ~7 days for IgG3) and is exploited by FcRn-targeting therapies (efgartigimod in myasthenia gravis, rozanolixizumab)
• Selective IgA deficiency (IgA <7 mg/dL) is the most common primary immunodeficiency (~1:500); usually asymptomatic; risk of anaphylaxis to blood products containing IgA

References

1. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008;112(5):1570-1580.
2. Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2022;40:413-442.
3. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.
4. Muramatsu M, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID). Cell. 2000;102(5):553-563.
5. Conley ME, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009;27:199-227.

Read this lecture as Markdown